Lipanthyl Supra 160mg Abbott medicine for hypercholesterol (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Fenofibrate

Ingredient

Composition information	Content
Fenofibrate	160mg

Uses

Indications

Lipanthyl SupRA 160 mg is indicated in the following cases:

Hyper hyperchemical treatment or hyperklyceride blood or coordination (Type IIA, IIB, III, IV and V of blood lipid disorders) in patients do not respond to diets and other non -drug treatments (for example, measures to reduce weight or enhance physical activity), especially when there are other risk evidence.

Secondary hyperlotein hypertrophy if persistent blood lipoprotein abnormalities, even if the cause (for example: blood lipid disorders in diabetes).

Pharmacokic

fenofibrate is a substance of fibric acid, which has the effect of changing blood lipid levels in the intermediary through the activation of the peroxisome type alpha hyperactive activity (PPARα). Through the activation of PPARα, Fenofibrate increases the decomposition of lipids and the export of triglycerides -rich sub -fertilizers from plasma by activating lipoprotein lipase and reducing the production of apoprotein CIII.

The activation of PPARα also increases the synthesis of AI and AII apoprotein. The above starting efficiency for lipoprotein leads to reduced LDL and VLDL containing lipoprotein B and increases HDL containing AI and AII apoprotein.

Through the synthesis and catabolic change of VLDL components, Fenofibrate increases LDL clearance and low density LDL reduction, high -content substances in the forms of lipoprotein hyperthink in the circuit, a very common form of disorders in patients with high risk of coronary artery disease in the heart.

In clinical trials with fenofibrate, total cholesterol decreased by 20–25%, triglycerides fell by about 40–55%and HDL increased by about 10–30%.

In patients with hypercholesterol hypercemolity, when LDL -Cholesterol level increases by about 20–35%, the overall effect of cholesterol creates a decrease in the total cholesterol ratio compared to HDL - Cholesterol, LDL - Cholesterol compared to HDL - cholesterol, or APO B compared to AI AI, all of which create risk of arteriosclerosis. So far in long -term control clinical trials has not seen the results of fenofibrate in preventing complications of atherosclerosis or secondary atherosclerosis.

An external cholesterol condensation: tendons or tumors in yellow tumors (tuberous xanthoma) may be significantly reduced, even completely lost when treated with fenofibrate.

Patients with high fibrinogen levels are treated with fenofbrate that this parameter is significantly reduced as well as high LP (A) people. Performing inflammatory processes such as C Reactive Protein also decreased when treated with fenofibrate.

The effect of increasing urinary uric acid Export of fenofibrate led to a reduction of uric acid by about 25%, which is also a very beneficial support effect in patients with lipid disorders accompanied by hyperuricemia.

Fenofibrate has anti -platelet gathering effect on animal and clinical trials, reducing platelet aggregation created by ADP, Arachidonic and Epinephrine acid.

pharmacokinetics

absorption:

Maximum concentration in plasma (cmax) reached 4–5 hours after drinking. The maximum concentration in plasma is stable when treated continuously in all individuals. Fenofibrate increases absorption when taken at meals.

Distribution:

Fenofibric acid is strongly linked to plasma albumin (> 99%).

Metabolism:

Fenofibrate is not seen in a variable form in plasma, but only fenofibric acid is a main metabolite.

Era:

The remedy is mainly in urine. In fact, all the amount of drugs included within 6 days. Fenofibrate is produced mainly in the form of fenofibric acid and glucuronide complex. The sale time of fenofibric acid is 20 hours.

Before taking Lipanthyl Supra 160mg Abbott medicine for hypercholesterol (3 blisters x 10 tablets)

How to use

oral medication. Should take medicine after eating.

Dosage

Dosage recommended: 1 tablet/day.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? There is no specific antidote. If the overdose is suspected, symptomatic treatment should be treated and taken supportive measures when needed.

fenofibrate is not excluded when clinical.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using lipanthyl supra 160 mg, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Digestive: digestive disorders , stomach, intestines (abdominal pain, nausea, vomiting, diarrhea and flatulence) The average level.

Liver - Moderate increase in serum transaminase concentration.

Uncommon, 1/1000

Digestive: pancreatitis.

Hepatoa: The enlargement of gallstones.

skin: rash, itching, urticaria .

Muscle, connective tissue and bone: muscle pain spread, muscle inflammation, muscle contraction, muscle weakness.

Cardiovascular disease: Tagnetic thrombosis (pulmonary embolism, deep vein thrombosis). Neurology: headache .

Reproduction: Sexual decline.

Increase creanlinine and urea in serum, increased blood homocysteine levels.

Rare, 1/10000

Skin: Hair loss, sensitive skin with light with erythema, blisters or floating in the skin exposed to sunlight or artificial ultraviolet light (ultraviolet lights).

Blood: Hemoglobin and leukocytes.

Very rare, ADR

Hepatitis: Hepatitis.

Not determined frequency

Bone muscle, connective tissue and bone: Muscle globin.

Respiratory: interstitial lung disease.

Instructions on how to handle ADR

Notify the doctor the unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

lipanthyl supra 160 mg contraindicated in the following cases:

Children;

Pregnant or lactating women;

Patients with liver disability (including biliary obstruction and abnormal liver function constantly unknown);

Patients with severe renal impairment (Creatinine clearance

Hypersensitivity to fenofibrate and/or excipients;

History of allergic reactions to light or light poisoning during treatment with fenofibrate or with ketoprofen, acute or chronic pancreatitis, except for high cholecystitis, gallbladder ...;

Do not use lipanthyl supra for patients allergies to peanuts, peanuts, soy lecithin or products made from the above material because there is a risk of hypersensitivity reactions.

Caution when using

In cases of secondary cholesterol hyperplasia such as uncontrolled type 2 diabetes, thyroid failure, nephrotic syndrome, protein disorders, obstructive liver disease, alcoholism, should be appropriate before using fenofibrate.

Monitoring treatment response by determining serum lipid value (total cholesterol, ldl - cholesterol, triglyceride), if fully responded to a few months (for example, 3 months) should consider additional or use other alternative therapies.

For patients with high blood fat using estrogen or contraceptives containing estrogen, it is clear that increased blood fat is primary or secondary (maybe increased blood fat due to estrogen).

Liver function:

There have been reports on increased transaminase levels in some patients. Most of these cases only increase fleeting, few and almost asymptomatic. It is recommended to monitor the concentration of transaminase periodically every 3 months in the first 12 months of treatment and then periodically check.

Pay attention to patients with increased transaminase concentration and need to stop treatment if the AST and ALT concentration increases more than 3 times the upper limit of normal levels.

pancreatitis:

Cases of pancreatitis are recorded in patients using fenofibrate. This may indicate the failure of these medications in patients with serious hyperglyceride blood or secondary treatment due to biliary stones or sedimentation in the bile duct.

muscle:

There have been a report on muscle toxicity, including rare muscle globulin when using fibrate and other lipid medications. This disorder rate increases in the case of lowering blood albumin and renal failure.

The risk of progression of muscle globulin can be increased in patients with favorable factors for muscle and/or urinary organs, including: over 70 years old, personal history or families with genetic disorders, kidney failure, reducing thyroid activity, drinking a lot of alcohol. Must consider the benefits and risks when treating with fenofibrate for these objects.

Must think of muscle toxicity when the patient appears muscle pain, muscle inflammation with seizures of the painful muscle area, cramps and muscle weakness, increasing signs on CPK (concentration of 5 times more than normal levels). Stop treatment with fenofibrate in these cases.

Increased risk of muscle toxicity when the drug is used simultaneously with other fibrates or HMG-Coa Reductase inhibitors, especially in the case of previous muscle diseases. Therefore, it is necessary to be careful when prescribing fenofibrate with HMG-Coa Reductase inhibitors or other fenofibrate drugs for patients without a history of muscle disease but with severe hyperplasher disorders, along with the risk of high cardiovascular disease. It is necessary to strictly check the ability to cause muscle toxicity.

Recommendations for elderly patients such as adults. Because the drug contains lactose, the patient has a problem with galactose intolerance, lactase deficiency or galactose malabsorption is not used.

Kidney function:

Cause treatment in case of increased creatinine concentration by 50% of ULN (upper or normal limits). Consider measuring creatinine in the first 3 months of treatment.

The ability to drive and operate machinery

does not affect.

Pregnancy

Not enough data in using fenofibrate for pregnant women. Animal research does not see teratogenic effects. However, it has been observed signs of toxic fetuses at a toxic dose for maternal animal. Therefore, the drug should only be used during pregnancy when it has carefully evaluated the benefits and risks.

The period of breastfeeding

There is no data showing the ability to excrete in Fenofibrate and/or metabolites. The risk for breastfed babies has not been excluded. Therefore, Fenofibrate should not be used while breastfeeding.

Interactive drug

do not recommend combining fenofibrate and oral anticoagulant drugs. Fenofibrate increases the effects of anticoagulants and may increase the risk of bleeding. However, if this combination is required, one third of the dose should be reduced to anticoagulant drugs at the time of starting treatment and then gradually adjusting if necessary compared to Inr (international standard ratio).

A few cases of reversible kidney function have been recorded when using fenofibrate and cyclosporine simultaneously. Strictly monitor kidney function and stop treatment with fenofibrate in case of serious change of test index.

HMG-COA Reductase inhibitors and other fenofibrates may increase the risk of muscle poisoning if coordinated with other fibrates or HMG-COA Reductase inhibitors. Be careful with these combination treatments and closely monitor the signs of muscle poisoning.

At the concentration of treatment, the weak inhibitors CYP2C19 and CYP2A6, which inhibit the mild - medium level with CYP2C9. Strict monitoring patients must simultaneously use fenofibrate and metabolic drugs via CYP2C19, CYP2A6, especially CYP2C9, with accurate treatment index, recommended adjusting the dose of these drugs if necessary.

Storage

Keep the drug in the original packaging. Store at a temperature not exceeding 30ºC.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.